Jaymin Kang

Philadelphia

Drug Information Specialist at The Cardiology Advisor

Drug Information Specialist at Monthly Prescribing Reference

Featured in: Favicon

empr.com

thecardiologyadvisor.com Favicon

clinicaladvisor.com Favicon

psychiatryadvisor.com Favicon

cancertherapyadvisor.com Favicon

renalandurologynews.com Favicon

endocrinologyadvisor.com Favicon

neurologyadvisor.com Favicon

infectiousdiseaseadvisor.com Favicon

dermatologyadvisor.com + 7 more

Articles

Novel Dexmethylphenidate Formulation Improves Pediatric ADHD Symptoms

1 day ago | psychiatryadvisor.com | Jaymin Kang

Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD). CTx-1301 is a novel proprietary formulation of , a stimulant that increases norepinephrine and dopamine activity in the brain.
Study Shows IV Ibuprofen Safe, Effective for Managing Pain in Older Adults

1 day ago | rheumatologyadvisor.com | Jaymin Kang

Intravenous ibuprofen reduced postoperative pain and opioid consumption in older adults, according to research published in Clinical Therapeutics. To assess the safety and efficacy of IV ibuprofen in older adults, researchers conducted a post hoc subgroup analysis with data from 4 prospective clinical studies (2 placebo-controlled phase 3 studies and 2 open-label phase 4 trials) in which IV ibuprofen was given to treat pain and/or fever in hospitalized patients.
FDA Approves Ustekinumab Biosimilar Starjemza

2 days ago | rheumatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Starjemza® (ustekinumab-hmny), a biosimilar to Stelara® (ustekinumab), for the treatment of various chronic inflammatory diseases.
Amneal Recalls Oral Antibiotic Over Contamination Issue

3 days ago | empr.com | Jaymin Kang

Amneal Pharmaceuticals is recalling 3 lots of Sulfamethoxazole/Trimethoprim Tablets, USP, 400mg/80mg due to Aspergillus contamination. Sulfamethoxazole/Trimethoprim is indicated for the treatment of urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris.
Malaria Prevention Therapy Arakoda Now Available in 8-Count Bottle

3 days ago | empr.com | Jaymin Kang

Arakoda® (tafenoquine) is now available in an 8-count bottle format, according to 60 Degrees Pharmaceuticals. Arakoda, an 8-aminoquinolone antimalarial, was approved in 2018 for the prophylaxis of malaria in patients aged 18 years and older. It is active against all stages of Plasmodium species. According to the Company, the new bottle presentation may be more beneficial for patients who are making shorter trips to malaria endemic locations.
Nubeqa Approval for Metastatic Castration-Sensitive Prostate Cancer Expanded

3 days ago | empr.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Nubeqa® (darolutamide), an androgen receptor inhibitor, for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). Previously, it was only approved for mCSPC in combination with docetaxel. Darolutamide works by competitively inhibiting androgen binding, androgen receptor nuclear translocation, and androgen receptor-mediated transcription.
Oral Tebipenem HBr Noninferior to IV Imipenem-Cilastatin for Complicated UTI

3 days ago | infectiousdiseaseadvisor.com | Jaymin Kang

Topline data were announced from a phase 3 trial evaluating tebipenem pivoxil hydrobromide (HBr) in patients with complicated urinary tract infections (cUTIs). Tebipenem HBr is an investigational oral antibiotic in the carbapenem class. The randomized, double-blind, phase 3 PIVOT-PO trial (ClinicalTrials.gov Identifier: NCT06059846) included 1690 adults aged 18 years and older with cUTI or acute pyelonephritis.
FDA Approves Ustekinumab Biosimilar Starjemza

5 days ago | dermatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Starjemza® (ustekinumab-hmny), a biosimilar to Stelara® (ustekinumab), for the treatment of various chronic inflammatory diseases.
Sparsentan Under Review for Focal Segmental Glomerulosclerosis

1 week ago | renalandurologynews.com | Jaymin Kang

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). Sparsentan, an oral endothelin and angiotensin II receptor antagonist, is currently approved under the brand name Filspari® to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
Zevtera Availability Provides New Option for Serious Bacterial Infections

1 week ago | dermatologyadvisor.com | Jaymin Kang

Zevtera® (ceftobiprole medocaril sodium for injection) is now available for the treatment of: adults with Staphylococcus aureus bloodstream infections (bacteremia; SAB), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and pediatric patients 3 months to less than 18 years of age with community-acquired bacterial pneumonia (CABP).